FAIRFIELD, N.J., July 28 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. announced today that The Skin Cancer Screening Tour, sponsored by Bradley’s Doak Dermatologics subsidiary in partnership with The Skin Cancer Foundation, has screened to date more than 3400 individuals. In addition, the media coverage surrounding the Screening Tour has helped raise awareness of the importance of visiting a dermatologist, even beyond the scope of the Tour, for early detection of skin cancer.
At each stop on the Tour, local dermatologists volunteer their time in the 38-foot Mobile Diagnosis Vehicle (MDv), custom-built by Doak Dermatologics, performing free skin cancer examinations in two fully outfitted exam rooms. To date, almost 40% of those screened were identified as requiring further medical attention for a cancer-related skin condition.
Among the more than 3400 people screened, participating physicians have identified the following:
* 825 people with Actinic Keratosis Actinic Keratosis (AK) affects 1.3 million people annually. AK is the most common type of precancerous skin lesion. If left untreated, AK can lead to Squamous Cell Carcinoma. * 94 with Squamous Cell Carcinoma Squamous Cell Carcinoma (SCC) is a form of skin cancer that affects 200,000 Americans each year. SCCs can spread quickly. * 303 with Basal Cell Carcinoma Basal Cell Carcinoma (BCC) is a common form of skin cancer, affecting more than 800,000 Americans annually. * 37 with Melanoma Melanoma is the most serious form of skin cancer and has increased more rapidly than any other form of skin cancer during the past 10 years. Similar to previously mentioned conditions, if melanoma is diagnosed and removed early, it is almost 100 percent curable.
Doak created The Skin Cancer Screening Tour in response to the Company’s knowledge of the prevalence of skin cancer, heightened by the acquisition of a major topical therapy for the precancerous skin condition Actinic Keratosis. More than 1.3 million people will be diagnosed with skin cancer this year, and in the US, there are more cases of skin cancer than breast, prostate, lung and colon cancers combined. Because early detection and treatment are critical to a positive outcome, Doak launched The Skin Cancer Screening Tour as a public service.
In addition to carrying out screenings on the MDv, The Skin Cancer Screening Tour is conducting a skin cancer awareness campaign in major media outlets across the country, urging people to be screened whether aboard the MDv or by their local dermatologist. For those who cannot visit the MDv, Doak has created a website with a full listing of dermatologists by zip code. To date, information on the Tour has appeared in over 250 newspapers and national magazines and on numerous local TV and radio stations, enabling millions of people to be exposed to the message. For example, on May 29, 2006, Bradley President and CEO, Daniel Glassman, appeared on America Health Radio with Scott Broder to discuss the importance of regular skin cancer screenings. According to Mr. Broder, this segment was “one of the most popular and well-received shows ever broadcast on American Health Radio.”
Mr. Glassman stated, “Through its Doak Dermatologics subsidiary, Bradley is extremely proud to be a part of this important effort to draw attention to the importance of annual screenings and early detection for skin cancer. We are particularly grateful to the local dermatologists who have provided their skill and time to this important initiative. We recognize there is a skin cancer epidemic, and drawing the public’s attention to the necessity of regular visits to dermatologists is a critical step in gaining control of it. We believe that the statistics from this tour show that we are helping to generate important awareness, and encouraging people to visit their dermatologist.”
The MDv has conducted screenings in San Francisco; Los Angeles; Phoenix; Dallas; Houston; Tampa; Miami; West Palm Beach; Atlanta; Nashville; Avalon, New Jersey; Chicago; and is currently at locations in Washington, DC, including the Pentagon. The Tour will be traveling through the Northeastern US during the second half of 2006 and will be extended into 2007.
To learn more about The Skin Cancer Screening Tour and find a list of upcoming stops, please visit www.skincancerscreeningtour.com.
Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and 38 international markets. Bradley’s success is based on the strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands, Enhances these brands with line extensions and improved formulations and Grows the products through promotion, advertising and selling activities to optimize life cycle management. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in topical therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Important announcement: July 26-30, 2006 - Doak Dermatologics will be exhibiting at the Summer Meeting of the American Academy of Dermatology, held in San Diego, CA. August 7-10, 2006 - Doak Dermatologics will be exhibiting at the American Podiatric Medical Association, held in Las Vegas, NV. Daniel Glassman will present at the RBC’s Healthcare Conference, to be held in New York City, December 12-14, 2006. Daniel Glassman will present at the Raymond James & Associates 28th Annual Institutional Investors Conference, to be held at the Hyatt Regency Grand Cypress in Orlando, FL., March 4-7, 2007.
Bradley Pharmaceuticals, Inc.
CONTACT: Anthony Griffo, Investor Relations of Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 313
